	US 11,965,201 B2
	Arginine supplementation to improve efficiency in gas fermenting acetogens
Kaspar Valgepea, Brisbane (AU); Michael Koepke, Chicago, IL (US); James Bruce Yarnton Haycock Behrendorff, Frederiksberg (DK); Esteban Marcellin, Brisbane (AU); Lars K. Nielsen, Brisbane (AU); and Renato de S. P. Lemgruber, Brisbane (AU)
Assigned to LanzaTech NZ, Inc., Skokie, IL (US)
Filed by LanzaTech NZ, Inc., Skokie, IL (US)
Filed on Mar. 16, 2021, as Appl. No. 17/203,617.
Application 17/203,617 is a continuation of application No. 15/368,521, filed on Dec. 2, 2016, granted, now 10,995,347, issued on May 4, 2021.
Claims priority of provisional application 62/262,886, filed on Dec. 3, 2015.
Claims priority of provisional application 62/262,888, filed on Dec. 3, 2015.
Prior Publication US 2021/0230648 A1, Jul. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12P 7/56 (2006.01); C12N 1/20 (2006.01); C12N 1/38 (2006.01); C12N 9/06 (2006.01); C12N 9/10 (2006.01); C12N 9/12 (2006.01); C12N 9/78 (2006.01); C12N 9/90 (2006.01); C12N 15/52 (2006.01); C12P 7/04 (2006.01); C12P 7/06 (2006.01); C12P 7/18 (2006.01); C12P 7/40 (2006.01); C12P 7/54 (2006.01)

CPC C12P 7/56 (2013.01) [C12N 1/20 (2013.01); C12N 1/38 (2013.01); C12N 9/0016 (2013.01); C12N 9/1018 (2013.01); C12N 9/1029 (2013.01); C12N 9/1217 (2013.01); C12N 9/78 (2013.01); C12N 9/90 (2013.01); C12N 15/52 (2013.01); C12P 7/04 (2013.01); C12P 7/065 (2013.01); C12P 7/18 (2013.01); C12P 7/40 (2013.01); C12P 7/54 (2013.01); C12Y 104/01012 (2013.01); C12Y 201/03003 (2013.01); C12Y 207/02002 (2013.01); C12Y 305/03006 (2013.01); C12Y 501/01012 (2013.01); C12Y 504/03005 (2013.01); Y02E 50/10 (2013.01)]

6 Claims

1. A method for improving efficiency of arginine co-utilization with one or more gaseous substrates selected from the group consisting of CO, H₂and CO₂, the method comprising culturing a genetically engineered C1-fixing bacterium comprising one or more genetic modifications selected from the group consisting of:

i) a disruptive mutation in an arginine transporter;

ii) overexpression of one or more endogenous enzymes selected from the group consisting of arginine deiminase (EC 3.5.3.6), ornithine carbomyltransferase (putrescine carbomyltransferase) (EC 2.1.3.3), carbamate kinase (EC 2.7.2.2), ornithine racemase (EC 5.1.1.12), ornithine aminomutase (EC 5.4.3.5), and 2,4-diaminopentanoate dehydrogenase (EC 1.4.1.12);

iii) expression of one or more mutated endogenous enzymes selected from the group consisting of arginine deiminase (EC 3.5.3.6), ornithine carbomyltransferase (putrescine carbomyltransferase) (EC 2.1.3.3), carbamate kinase (EC 2.7.2.2), ornithine racemase (EC 5.1.1.12), ornithine aminomutase (EC 5.4.3.5), and 2,4-diaminopentanoate dehydrogenase (EC 1.4.1.12); and

iv) expression of one or more exogenous enzymes selected from the group consisting of arginine deiminase (EC 3.5.3.6), ornithine carbomyltransferase (putrescine carbomyltransferase) (EC 2.1.3.3), carbamate kinase (EC 2.7.2.2), ornithine racemase (EC 5.1.1.12), ornithine aminomutase (EC 5.4.3.5), and 2,4-diaminopentanoate dehydrogenase (EC 1.4.1.12) wherein arginine is a sole nitrogen source.